Table 1.
Characteristics of the 58 patients initially diagnosed with EGD
| Number of patients | 58 |
| Sex | Male: 13 (22.4%); female: 45 (77.6%) |
| Age (years) | 43.6±13.3 |
| Observation period (years) | 5.8 (range 0.6–29.7) |
| Smoking rate | 12/58 (20.7%) |
| Estimated thyroid volume (mL, n=35) | 13.1 g (range 5.3–39.8) |
| TBII (IU/L) (Cosmic:Roche =31:25) | 2.5 (range 0.6–47.2) |
| Positive rate | 41/55 (74.5%) |
| Using Cosmic | 21/31 (67.7%) |
| Using Roche | 20/25 (80.0%) |
| TSAb (%, n=44) | 257 (range 110–1,448) |
| Positive rate | 31/44 (70.5%) |
| Sum of lid fissures* (mm) | 34 (range 19–49) |
| Proptosis* (mm) | 18 (range 11–36) |
| Eight extraocular muscles* (cm2) | 2.43 (range 1.11–5.80) |
| Course of thyroid function | |
| Remained euthyroid | 42 (72.4%), male: 7; female: 35; mean age, 43.2±12.4 years |
| Developed hyperthyroidism | 14 (24.1%), male: 6; female: 8; mean age, 42.9±16.9 years |
| Developed hypothyroidism | 2 (3.4%), male: 0; female: 2; ages 50 and 54 years |
| Duration until development of dysfunction (months) | |
| Hyperthyroidism | 28.5 (range 3–124) |
| Hypothyroidism | 25 and 39 |
Notes:
*
Right + left. Numerical values are reported as the median, with the exception of age (mean ± SD).
Abbreviations: EGD, euthyroid Graves’ disease; TBII, thyrotropin-binding inhibitory immunoglobulin; TSAb, thyroid-stimulating immunoglobulin.